证券日报网讯2月26日，力生制药（002393）在互动平台回答投资者提问时表示，力生制药为深交所上 市企业，属医药制造及生物医药行业，是国家高新技术企业、国家企业技术中心、国家级绿色工厂， 2022年入选国务院国资委"科改示范企业"。公司成立于1951年，主营药品研发、生产与销售，产品覆盖 心脑血管、消化、抗感染等15大类共296个品种，拥有专利授权111项、注册商标189个。公司在缓控释 制剂领域布局较早，核心技术包括以激光打孔为基础的渗透泵缓控释技术。相关技术已应用于甲磺酸多 沙唑嗪缓释片等产品，可实现药物长效平稳释放。公司围绕渗透泵制剂相关设备拥有自主专利，生产装 备具备较高自动化水平与生产效率。目前公司已初步建成缓控释制剂平台，为天津市缓控释及固体分散 体药物制剂重点实验室，同时拥有骨架缓释、缓释微丸、固体分散体等多项制剂技术，形成了较为完整 的制剂技术体系，在高端制剂领域实现了关键装备与辅料的国产化突破，是国内少数具备渗透泵缓控释 制剂产业化能力的企业之一。 ...

仟源医药（300254）(300254.SZ)公告，公司董事会授权经营层以自有资金与舟山荣豪贸易有限公司(简 称"舟山荣豪")联合参与海力生集团有限公司所持有浙江仟源海力生制药（002393）有限公司(简称"仟源 海力生")40%股权司法拍卖，公司与舟山荣豪各竞拍20%仟源海力生股权。于2026年2月25日，根据浙江 省宁波市鄞州区人民法院淘宝网司法拍卖网络平台的公告信息，公司与舟山荣豪联合以1.55亿元价格竞 得仟源海力生40%股权，公司持有仟源海力生股权将增加至80%。 ...

Core Viewpoint - The report highlights the growth in the chemical raw materials and products manufacturing industry in China, indicating a positive trend in the number of enterprises and overall market potential from 2026 to 2032 [1] Industry Summary - As of January to December 2025, the number of enterprises in the chemical raw materials and products manufacturing industry reached 27,102, an increase of 815 compared to the previous year, representing a year-on-year growth of 3.1% [1] - This sector accounts for 5.15% of the total industrial enterprises in China, reflecting its significance within the broader industrial landscape [1] - The report is based on data from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - The report mentions several listed companies in the chemical sector, including Hainan Haiyao (000566), Northeast Pharmaceutical (000597), and others, indicating a diverse range of players in the market [1] - Zhiyan Consulting provides comprehensive industry research reports, business plans, feasibility studies, and customized services, emphasizing its role in supporting investment decisions in the chemical industry [1]

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the market entry of its raw material drug, Adenosine Phosphate, which is expected to enhance its market competitiveness and create synergy with its formulation products [1]. Group 1: Product Approval - Lifesun Pharmaceutical announced the receipt of the approval notice for the market entry of Adenosine Phosphate raw material drug [1]. - Adenosine Phosphate, previously known as Vitamin B4, is a crucial component for nucleic acids and coenzymes, participating in the synthesis of DNA and RNA [1]. - The drug is clinically used to prevent and treat leukopenia caused by various reasons, including acute granulocytopenia, particularly due to chemotherapy, radiation therapy, and benzene poisoning [1]. Group 2: Market Impact - The approval of Adenosine Phosphate is expected to facilitate industrial synergy with the company's formulation products [1]. - This development is anticipated to enhance the company's market competitiveness [1].

Overview - Tianjin Lifeng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the listing application of Adenine Phosphate raw material [2] Product Information - The product, Adenine Phosphate, is a chemical raw material with a molecular weight of 233.12 and a molecular formula of C5H5N5·H3PO4 [2] - It is used clinically to prevent and treat leukopenia caused by various reasons, particularly in cases related to chemotherapy, radiation therapy, and benzene poisoning [2] Impact on the Company - The approval of this product's listing application is expected to enhance the company's market competitiveness by creating industrial synergy with its formulation products [3]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), has received approval from the National Medical Products Administration for the marketing application of Adenosine Phosphate raw material, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - Lifesun Pharmaceutical has been granted a marketing approval notice for Adenosine Phosphate raw material [1] - Adenosine Phosphate, previously known as Vitamin B4, is essential for the synthesis of DNA and RNA, playing a crucial role in maintaining metabolic functions in living organisms [1] - The clinical applications of Adenosine Phosphate include the prevention and treatment of leukopenia caused by various factors, particularly in patients undergoing chemotherapy and radiation therapy, as well as those affected by benzene poisoning [1]

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of adenine phosphate raw material, which is expected to enhance its market competitiveness and create synergy with its formulation products [1] Group 1: Company Announcement - Lifesun Pharmaceutical announced the receipt of the approval notice for the listing application of adenine phosphate raw material from the National Medical Products Administration [1] - Adenine phosphate is a component of nucleic acids and coenzymes, involved in the synthesis of DNA and RNA in the body, and is clinically used to prevent and treat leukopenia caused by various reasons [1] Group 2: Market Implications - The approval of adenine phosphate raw material is expected to facilitate industrial synergy with the company's formulation products, thereby enhancing market competitiveness [1]

证券代码：002393 证券简称：力生制药 公告编号：2026-011 天津力生制药股份有限公司 关于磷酸腺嘌呤原料药通过上市申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"本公司"）收到国家药品监督管理局 颁发的关于磷酸腺嘌呤原料药《化学原料药上市申请批准通知书》（通知书编号： 2026YS00104），该品种通过化学原料药上市申请。 二、该品种的基本情况 通用名称：磷酸腺嘌呤 英文名称：Adenine Phosphate 汉语拼音：Linsuan Xianpiaoling 化学名：6-氨基嘌呤磷酸盐 化学结构式： 分子量：233.12 分子式：C5H5N5·H3PO4 CAS 号：70700-30-0 生产企业：天津力生制药股份有限公司 申请内容：化学原料药上市申请 受理号：CYHS2460726 审批结论：通过化学原料药上市申请 1 三、该品种的相关信息 天津力生制药股份有限公司 董事会 2026 年 2 月 7 日 2 磷酸腺嘌呤，曾用名维生素 B4，为核酸和辅酶的组成成分，参与体内 DN ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至本公告日，天津力生制药股份有限公司（以下简称"公司"或"本公司"）回购专 用证券账户持股数量为699,980股，根据《中华人民共和国公司法》《深圳证券交易所上市 公司自律监管指引第9号——回购股份》等相关规定，该部分股票不参与本次利润分配。公 司以现有总股本257,586,843股扣除已回购库存股699,980股后的256,886,863股为基数，向 全体股东每10股派3.00元人民币（含税），不送红股，不以公积金转增股本。 2、因公司回购专户的股份不参与2025年前三季度权益分派，本次实际现金分红的总金 额=实际参与分配的总股本*分配比例，即256,886,863股*0.30元/股=77,066,058.90元人民 币；本次权益分派实施后除息价格计算时，每股现金红利应以0.2991847元/股计算（每股现 金红利=现金分红总额/总股本，即77,066,058.90元÷257,586,843股=0.2991847元/股，计算 结果不四舍五入，保留小数点后七位）。在保证本次权益分派方案不变的前提 ...